C. Daniel Myers Net Worth

The estimated Net Worth of C. Daniel Myers is at least $1.57 Millón dollars as of 20 August 2020. Mr. Myers owns over 5,000 units of Alimera Sciences stock worth over $30,846 and over the last 14 years he sold ALIM stock worth over $712,435. In addition, he makes $830,253 as Non-Executive Chairman of the Board at Alimera Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Myers ALIM stock SEC Form 4 insiders trading

C has made over 23 trades of the Alimera Sciences stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of ALIM stock worth $33,650 on 20 August 2020.

The largest trade he's ever made was exercising 55,147 units of Alimera Sciences stock on 11 October 2016 worth over $73,346. On average, C trades about 7,961 units every 75 days since 2010. As of 20 August 2020 he still owns at least 5,578 units of Alimera Sciences stock.

You can see the complete history of Mr. Myers stock trades at the bottom of the page.

C. Daniel Myers biography

C. Daniel Myers serves as Non-Executive Chairman of the Board of the Company. He has served as a director since the founding of the Company in 2003. He served as our Chief Executive Officer from 2003 until January 2019, when he retired from that role, was elected Chairman of the Board and became a consultant to us. Before co-founding the Company, Mr. Myers was an initial employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics) and served as its Vice President of Sales and Marketing from 1991 to 1997 and as President from 1997 to 2003. In addition, Mr. Myers served on the board of directors of Ocular Therapeutix, Inc. from 2009 to 2012. Mr. Myers currently serves as the Interim CEO of Leo Lens Technology, Inc (Leo Lens Pharma). Mr. Myers holds a B.S. in Industrial Management from the Georgia Institute of Technology. The Board believes that Mr. Myers should continue to serve as a director of the Company, in light of its business and structure, for the following reasons: his valuable contributions to the Company in recent years and his 37 years of ophthalmic pharmaceutical experience, including over 20 years in the role of president or chief executive officer.

What is the salary of C Myers?

As the Non-Executive Chairman of the Board of Alimera Sciences, the total compensation of C Myers at Alimera Sciences is $830,253. There are 1 executives at Alimera Sciences getting paid more, with Richard Eiswirth having the highest compensation of $977,025.

How old is C Myers?

C Myers is 66, he's been the Non-Executive Chairman of the Board of Alimera Sciences since 2019. There are 2 older and 13 younger executives at Alimera Sciences. The oldest executive at Alimera Sciences Inc. is James Largent, 70, who is the Lead Independent Director.

What's C Myers's mailing address?

C's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.

Insiders trading at Alimera Sciences

Over the last 14 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo y Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.

What does Alimera Sciences do?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

Complete history of Mr. Myers stock trades at Alimera Sciences y Kala Bio

Alimera Sciences executives and stock owners

Alimera Sciences executives and other stock owners filed with the SEC include:

• Richard Eiswirth,
  President, Chief Executive Officer, Director
• C. Daniel Myers,
  Non-Executive Chairman of the Board
• Richard S. Eiswirth Jr.,
  Pres, CEO & Director
• David Holland,
  Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets
• Philip Ashman,
  Chief Operating Officer, Senior Vice President - Commercial Operations Europe
• David R. Holland,
  Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets
• Dr. Philip Ashman,
  COO & Sr. VP of Commercial Operations - Europe
• Charles Daniel Myers,
  Non-Exec. Chairman & Consultant
• James Largent,
  Lead Independent Director
• John Marco,
  Investor Relations
• Mary Szela,
  Independent Director
• John Snisarenko,
  Independent Director
• Peter Pizzo,
  Independent Director
• Garheng Kong,
  Independent Director
• Brian Halak,
  Independent Director
• Samer Kaba,
  Chief Medical Officer
• Phil Jones,
  Chief Financial Officer
• Dr. David Dyer,
  Chief Retina Specialist
• Christopher S. Visick,
  VP, Gen. Counsel & Sec.
• J. Philip Jones,
  Chief Financial Officer
• Calvin W. Roberts,
  Director
• Glen Bradley,
  Director
• James E Deerfield Mgmt L.P....,
  
• Mark J Brooks,
  Director
• Kenneth Green,
  SVP & Chief Scientific Officer
• L.P.Mitchell Kateo'driscoll...,
  
• Alto Investors Lp Palo,
  
• Russell Skibsted,
  Chief Financial Officer & SVP
• Capital, Llc Armistice Capi...,
  
• Patrick Lee,
  10% owner
• Management Viii, L.L.C.Sofi...,
  
• Partners Vi, L.P.Blair Jame...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Jesse I Treu,
  10% owner
• Venture Management Co Iv Ll...,
  
• Philip R Tracy,
  Director
• Susan Caballa,
  SEE REMARKS
• Kathleen K Schoemaker,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• James C Blair,
  10% owner
• Nicole Vitullo,
  10% owner
• Anders D Hove,
  Director
• Bryce Youngren,
  Director
• Brian H Dovey,
  10% owner
• Vi Associates, L.P. Dp,
  10% owner
• Associates Iv L P Venrock M...,
  
• Associates Vi, Llc Mumma Mi...,
  
• Associates Vii, Llc Mumma M...,
  
• Associates V, Llc Mumma Mit...,
  
• L.P.Bock Louis Cmitchell Ka...,
  
• Adam Morgan,
  Director
• Stanley Morgan,
  10% owner
• Todd Michael Wood,
  President of U.S. Operations
• Roger Sawhney,
  Director
• Adam Velan Capital Investme...,
  
• Partners Lpjohnson David Ed...,
  
• Jason M. Werner,
  Chief Operating Officer
• Erin Parsons,
  
• Michael Kaseta,
  
• Ross D De Mont,
  
• Margaret Pax,
  
• Elliot Maltz,
  Chief Financial Officer